This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anaissie, E. J.
Right arrow Articles by Pietrelli, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anaissie, E. J.
Right arrow Articles by Pietrelli, L. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 1998, p. 606-611, Vol. 42, No. 3
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Treatment of Invasive Fungal Infections in Renally Impaired Patients with Amphotericin B Colloidal Dispersion

Elias J. Anaissie,1,* Gloria N. Mattiuzzi,2 Carole B. Miller,3 Gary A. Noskin,4 Marc J. Gurwith,5 Richard D. Mamelok,5 and Larry A. Pietrelli5

University of Arkansas for Medical Sciences, Little Rock, Arkansas1; Unidad Onco-Hematologica, San Carlos de Bariloche, Argentina2; The Johns Hopkins University School of Medicine, Baltimore, Maryland3; Northwestern Memorial Hospital and Northwestern University Medical School, Chicago, Illinois4; and SEQUUS Pharmaceuticals, Inc., Menlo Park, California5

Received 10 July 1997/Returned for modification 12 September 1997/Accepted 6 November 1997

Amphotericin B colloidal dispersion (ABCD) is a new formulation of conventional amphotericin B designed to minimize drug distribution in the kidney and reduce nephrotoxicity. We studied the safety and efficacy of ABCD in 133 renally compromised patients with invasive fungal infections. Patients had either nephrotoxicity from amphotericin B or preexisting renal disease. Intravenous treatment with ABCD (4 mg/kg of body weight daily) was administered for up to 6 weeks. Evaluations included clinical response to treatment and adverse events, with emphasis on changes in serum creatinine levels. ABCD did not appear to have an adverse effect on renal function: mean serum creatinine level tended to decrease slightly with days on therapy, and increases were not dose related. Complete or partial response to treatment was reported for 50% of the 133 intent-to-treat patients and 67% of the 58 evaluable patients.

* Corresponding author. Mailing address: University of Arkansas for Medical Sciences, 4301 West Markham, Slot 508, Little Rock, AR 72205. Phone: (501) 686-8250. Fax: (501) 686-6442. E-mail: anaissie{at}exchange.uams.edu.

Antimicrobial Agents and Chemotherapy, March 1998, p. 606-611, Vol. 42, No. 3
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Paterson, D. L., David, K., Mrsic, M., Cetkovsky, P., Weng, X.-H., Sterba, J., Krivan, G., Boskovic, D., Lu, M., Zhu, L.-P., on behalf of the PRoACT Investigators, (2008). Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC(R): data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry. J Antimicrob Chemother 62: 1392-1400 [Abstract] [Full Text]  
  • Blyth, C. C., Palasanthiran, P., O'Brien, T. A. (2007). Antifungal Therapy in Children With Invasive Fungal Infections: A Systematic Review. Pediatrics 119: 772-784 [Abstract] [Full Text]  
  • Linder, N., Klinger, G., Shalit, I., Levy, I., Ashkenazi, S., Haski, G., Levit, O., Sirota, L. (2003). Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother 52: 663-667 [Abstract] [Full Text]  
  • Bellmann, R., Egger, P., Gritsch, W., Bellmann-Weiler, R., Joannidis, M., Kaneider, N., Dunzendorfer, S., Wiedermann, C. J. (2003). Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration. J Antimicrob Chemother 51: 671-681 [Abstract] [Full Text]  
  • Hossain, M. A., Maesaki, S., Razzaque, M. S., Tomono, K., Taguchi, T., Kohno, S. (2000). Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B. J Antimicrob Chemother 46: 263-268 [Abstract] [Full Text]  
  • Van Etten, E. W. M., Stearne-Cullen, L. E. T., Ten Kate, M. T., Bakker-Woudenberg, I. A. J. M. (2000). Efficacy of Liposomal Amphotericin B with Prolonged Circulation in Blood in Treatment of Severe Pulmonary Aspergillosis in Leukopenic Rats. Antimicrob. Agents Chemother. 44: 540-545 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»